Arrowhead Pharmaceuticals, Inc. (ARWR)
86.34
-0.15
(-0.17%)
USD |
NASDAQ |
Sep 04, 16:00
86.95
+0.61
(+0.71%)
After-Hours: 20:00
Arrowhead Pharmaceuticals SG&A Expense (TTM) : 172.57M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 172.57M |
| March 31, 2026 | 156.39M |
| December 31, 2025 | 143.05M |
| September 30, 2025 | 123.94M |
| June 30, 2025 | 112.64M |
| March 31, 2025 | 105.40M |
| December 31, 2024 | 102.07M |
| September 30, 2024 | 98.76M |
| June 30, 2024 | 96.96M |
| March 31, 2024 | 97.02M |
| December 31, 2023 | 95.17M |
| September 30, 2023 | 92.55M |
| June 30, 2023 | 100.00M |
| March 31, 2023 | 109.38M |
| December 31, 2022 | 120.42M |
| September 30, 2022 | 124.43M |
| June 30, 2022 | 129.80M |
| March 31, 2022 | 115.10M |
| December 31, 2021 | 97.18M |
| September 30, 2021 | 80.98M |
| June 30, 2021 | 57.85M |
| March 31, 2021 | 50.16M |
| December 31, 2020 | 50.14M |
| September 30, 2020 | 52.28M |
| June 30, 2020 | 48.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 42.34M |
| December 31, 2019 | 31.35M |
| September 30, 2019 | 26.56M |
| June 30, 2019 | 22.72M |
| March 31, 2019 | 22.50M |
| December 31, 2018 | 20.85M |
| September 30, 2018 | 16.38M |
| June 30, 2018 | 11.46M |
| March 31, 2018 | 8.714M |
| December 31, 2017 | 6.655M |
| September 30, 2017 | 6.838M |
| June 30, 2017 | 7.226M |
| March 31, 2017 | 7.648M |
| December 31, 2016 | 9.843M |
| September 30, 2016 | 9.941M |
| June 30, 2016 | 10.36M |
| March 31, 2016 | 9.918M |
| December 31, 2015 | 7.797M |
| September 30, 2015 | 7.931M |
| June 30, 2015 | 7.640M |
| March 31, 2015 | 7.394M |
| December 31, 2014 | 8.243M |
| September 30, 2014 | 7.592M |
| June 30, 2014 | 6.455M |
| March 31, 2014 | 6.136M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Sarepta Therapeutics, Inc. | 436.74M |
| Revolution Medicines, Inc. | 330.91M |
| Moderna, Inc. | 965.00M |
| Intellia Therapeutics, Inc. | 136.25M |
| Denali Therapeutics, Inc. | 144.74M |